Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Buprenorphine TDS
Amarin Technologies S.A. Argentina flag Argentina
Abstract ID:
Transdermal system for the treatment of moderate to severe pain that do not adequately respond to non-opioid analgesics....
Contact Sergio Lucero
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Opioid Analgesic. Partial agonist of the Opioid receptors.

Buprenorphine patch is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Amarin has developed a 7-day Buprenorphine TDS using its drug-in-adhesive technology, and has completed a Phase I PK comparative with the original product.

Results indicated that our patch would be bioequivalent to BuTrans®/Norspan® with a lesser size and lower drug content than the RLD. Adhesion and dermal response were similar to the RLD.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
AMARIN patch has been licensed for the US market. AMARIN is seeking to license this product for Europe and RoW.
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development CLINICAL TRIALS
CORPORATION